ArticleInternational archives of allergy and immunology2026
The Clinical Importance of Component-Based Diagnostic Test in Patients Planned for Venom Immunotherapy.
Article in International archives of allergy and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVenom immunotherapy (VIT) is the most effective treatment approach for preventing severe systemic reactions caused by hymenoptera stings. In some cases, the detection of specific immunoglobulin E (IgE) positivity for both honeybee and wasp venoms can create diagnostic and therapeutic challenges. In this study, we aimed to evaluate the effectiveness of the Immulite 2000 3g Allergy component-based diagnostic test (CBDT) in determining true sensitization in patients with dual venom positivity who were scheduled for VIT.
methodsIn this prospective study, 66 patients who presented to the Immunology and Allergy Diseases outpatient clinic between January 2019 and December 2024 with a history of systemic reaction following a bee sting and who were indicated for VIT were evaluated.
resultsThe mean age of the patients was 46.3 ± 12.9 years, with a male predominance. Honeybee stings were the most common (50%). Forty-two patients had single-venom sensitization, while 22 had specific IgE positivity for both Apis mellifera and Vespula vulgaris. According to the CBDT results, 6 of the 22 patients had dual sensitization, while 7 patients had sensitization only to Vespula. Patients with indeterminate venom sensitization had higher Api m 1/Ves v 5 specific IgE ratios.
conclusionIn our study, using the Immulite 2000 3g Allergy CBDT results, venom sensitization could not be clearly determined in 41% of patients with dual sensitization to venom allergens, and true double sensitization was identified in only 27% of these patients. Therefore, we suggest that including additional species-specific antigens (especially Ves v 1) alongside in the Immulite 2000 3g Allergy CBDT panel could improve the detection of true sensitization. Furthermore, when supported by accurate and reliable clinical history, a specific IgE Api m 1/Ves v 5 ratio greater than 5 can represent a significant and useful hypothesis. However, further studies are needed to confirm this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.